FibroGen

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

FibroGen reports improved financials and readies for new therapy launches

FibroGen's financials improved in Q4 2022, with strong cash reserves.
Strategic focus on new therapy launches and pivotal Phase 3 data.
Progress in commercial manufacturing and readiness for potential launches.
Emphasis on FDA feedback for filing strategies and multiple efficacy endpoints.

FibroGen reports Q1 revenue growth, faces challenges in study results

FibroGen's Q1 2023 performance showed strong revenue but faced challenges with roxadustat's Phase 3 study results.
The company's strengths lie in commercial opportunities, financial stability, and adherence to rigorous data analysis methods.
Challenges include addressing study result concerns and uncertainties in funding tied to clinical milestones.
Opportunities exist in market expansion, especially in IPF treatment, and upcoming Phase 3 trials for pamrevlumab.

FibroGen reports revenue growth amidst challenges and promising opportunities

FibroGen's Q2 2023 performance showed revenue growth and cost reduction efforts.
The company faces challenges in pamrevlumab trials and patent validity issues in China.
However, opportunities lie in upcoming trial readouts and the early-stage oncology pipeline.
FibroGen's strategic pillars and commitment to cost savings are key strengths.

FibroGen reports robust Q3 earnings, eyes expansion amid market challenges

FibroGen's Q3 performance was strong, driven by revenue growth and promising trial results.
The company's strategic pillars and clear pricing strategies position it well for future growth.
While facing challenges like generic competition, FibroGen has opportunities for expansion and market differentiation.
Overall, FibroGen's financial health and pipeline developments indicate a positive outlook for the company.

FibroGen reports robust Q4 performance and eyes expansion opportunities

FibroGen's Q4 2023 earnings call showcased strong performance in China for roxadustat and provided a detailed financial update, addressing key inquiries from analysts.
The company's strategic pillars, emphasis on highest tolerable doses for efficacy, and promising Phase I results position FibroGen well for future growth and drug development.
While challenges exist in interpreting data and prioritizing studies, opportunities in expanding market reach, refining development strategies, and enhancing efficacy markers are evident.
Overall, FibroGen's proactive approach to addressing challenges and exploring opportunities underscores a commitment to innovation and growth in the pharmaceutical sector.

FibroGen reports robust earnings, eyes growth in China and oncology

FibroGen's Q1 2024 earnings call highlighted strong financial performance, promising drug developments, cost efficiencies, and strategic focus on future growth. Despite challenges like market competition and regulatory timelines, the company remains optimistic and proactive in pursuing opportunities for expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.

FibroGen, Inc. (NASDAQ:FGEN ) Q3 2022 Earnings Conference Call November 7, 2022 5:00 PM ET Company Participants Michael Tung - IR Executive Enrique Conterno - CEO & Director Juan Graham - CFO Mark Eisner - EVP & Chief Medical Officer Thane Wettig - EVP & Chief Commercial Officer Christine Chung - SVP, China Operations Conference Call Participants Jason Gerberry - Bank of America Merrill Lynch Jack Padovano - Stifel, Nicolaus & Company Michael Yee - Jefferies Alexander Nackenoff - Raymond James & Associates Andy Hsieh - William Blair & Company Yaron Werber - Cowen Paul Choi - Goldman Sachs Operator Good day, and thank you for standing by. Welcome to FibroGen's Third Quarter 2022 Earnings Call.

FibroGen, Inc. (FGEN) Q3 2022 Earnings Call Transcript

FibroGen (FGEN) delivered earnings and revenue surprises of -18.07% and 53.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

FibroGen (FGEN) Reports Q3 Loss, Misses Revenue Estimates

SAN FRANCISCO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter 2022 and provided an update on the company's recent developments.

FibroGen Reports Third Quarter 2022 Financial Results

SAN FRANCISCO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced a royalty monetization financing with NovaQuest Capital Management (NovaQuest) that will result in proceeds to FibroGen in the amount of $50 million, bringing non-dilutive capital to drive innovation and growth.

FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management

SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Stifel 2022 Healthcare Conference in New York, NY taking place on November 15, at 1:50 PM Eastern Time.

FibroGen to Participate at Stifel 2022 Healthcare Conference

FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: FibroGen (FGEN) Q3 Earnings Expected to Decline

SAN FRANCISCO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2022 financial results on Monday, November 7 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance.

FibroGen to Report Third Quarter 2022 Financial Results

Heron Therapeutics

ImmunityBio

Nkarta, Inc.

Relay Therapeutics, Inc.

Avidity Biosciences

Sana Biotechnology

Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.

7 Unknown Biotech Stocks That Could Rocket in 2023

- 141 MDS Patients Enrolled - - Topline Data Anticipated 1H:2023 -

FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS)

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), provides an update to KSF's continued investigation into FibroGen, Inc. (NasdaqGS: FGEN). On April 6, 2021, the Company disclosed that cardiovascular safety data it had previously submitted for the Phase 3 program of its Roxadustat product “included post-hoc changes to the stratification factors.” Then, on July 15, 2021, the FDA's Advis

FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Provides Update of its Investigation of the Officers and Directors of FibroGen, Inc. - FGEN

FibroGen, Inc. (NASDAQ:FGEN ) Q2 2022 Earnings Conference Call August 8, 2022 5:00 PM ET Company Participants Michael Tung - Corporate Strategy and IR Enrique Conterno - CEO Mark Eisner - Chief Medical Officer Juan Graham - CFO Thane Wettig - Chief Commercial Officer Chris Chung - Senior Vice President of China Operations Conference Call Participants Michael Yee - Jefferies Annabel Samimy - Stifel Andy Hsieh - William Blair Brendan Smith - Cowen Paul Choi - Goldman Sachs Jason Gerberry - Bank of America Operator Good day and thank you for standing by. Welcome to the FibroGen 's Second Quarter 2022 Earnings Call.

FibroGen, Inc. (FGEN) CEO Enrique Conterno on Q2 2022 Results - Earnings Call Transcript

FibroGen (FGEN) delivered earnings and revenue surprises of 17.02% and 18.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

FibroGen (FGEN) Reports Q2 Loss, Misses Revenue Estimates

SAN FRANCISCO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the second quarter 2022 and provided an update on the company's recent developments.

FibroGen Reports Second Quarter 2022 Financial Results

SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2022 financial results on Monday, August 8 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance.

FibroGen to Report Second Quarter 2022 Financial Results

Wilmington, Delaware--(Newsfile Corp. - July 20, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of FibroGen, Inc. (NASDAQ: FGEN) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-fibrogen-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating FibroGen, Inc.

SAN FRANCISCO, July 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the William Blair Biotech Focus Conference 2022 taking place the week of July 11, 2022.

FibroGen to Participate at William Blair Biotech Focus Conference 2022

- 73 Ambulatory DMD Patients Enrolled - - Topline Data Anticipated 2H:2023 -

FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into FibroGen, Inc. (NasdaqGS: FGEN). On April 6, 2021, the Company disclosed that cardiovascular safety data it had previously submitted for the Phase 3 program of its roxadustat product “included post-hoc changes to the stratification factors.” As a result of these changes, the complaint

FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of FibroGen, Inc. - FGEN

SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9 at 1:30pm EDT.

FibroGen to Present at Jefferies Healthcare Conference

Biohaven Pharmaceutical Hld

Intra-Cellular Therapies

Seagen

Should investors pay more attention to these biotech stocks?

What Stocks To Buy This Week? 4 Biotech Stocks To Know

FibroGen, Inc. (NASDAQ:FGEN ) Q1 2022 Earnings Conference Call May 9, 2022 5:00 PM ET Company Participants Michael Tung – Corporate Strategy/Investor Relations Enrique Conterno – Chief Executive Officer Mark Eisner – Chief Medical Officer Juan Graham – Chief Financial Officer Thane Wettig – Chief Commercial Officer Chris Chung – Senior Vice President of China Operations Conference Call Participants Michael Yee – Jefferies Andy Hsieh – William Blair Yaron Werber – Cowen Annabel Samimy – Stifel Operator Ladies and gentlemen, thank you for standing by and welcome to the FibroGen's First Quarter 2022 Earnings Conference Call. At this time all participants' lines are in a listen-only mode.

FibroGen, Inc.'s (FGEN) CEO Enrique Conterno on Q1 2022 Results - Earnings Call Transcript

SAN FRANCISCO, May 09, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2022 and provided an update on the company's recent developments.

FibroGen Reports First Quarter 2022 Financial Results

Wilmington, Delaware--(Newsfile Corp. - May 5, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of FibroGen, Inc. (NASDAQ: FGEN) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-fibrogen-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. is Investigating FibroGen, Inc.

FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FibroGen (FGEN) Expected to Beat Earnings Estimates: Should You Buy?

SAN FRANCISCO, April 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2022 financial results on Monday, May 9 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance.

News for FibroGen Stock (FGEN)